Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection; Phase 2 Data Presentations at The Liver Meeting® Detail SVR12 Rate

Press/Media: Press / Media

PeriodNov 13 2016

Media coverage

2

Media coverage

  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection; Phase 2 Data Presentations at The Liver Meeting® Detail SVR12 Rate
    Media name/outletBusiness Wire
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection; Phase 2 Data Presentations at The Liver Meeting® Detail SVR12 Rate
    Media name/outletBusiness Wire
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz